BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Azirkitug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Azirkitug\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05005403-2376@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Azirkitug: Phase 1 readout est. (NCT05005403)
DESCRIPTION:Azirkitug\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Study
  to Assess Adverse Events and Pharmacokinetics in Adult Participants With 
 Non-Small Cell Lung Cancer\, Head and Neck Squamous Cell Carcinoma and Oth
 er Solid Tumors\, Receiving Intravenous Infusion of Azirkitug Alone or in 
 Combination(s) With Budigalimab\, Bevacizumab\, or Telisotuzumab Adizuteca
 n\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/azirkitug#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05005403
URL:https://assetmemo.bio/drug/azirkitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
